News
The number of U.S. adults that are aware of GLP-1 drugs used for weight loss, such as Ozempic and Wegovy, has jumped ...
The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...
Bloomberg on MSN1d
Novo CFO: US Wegovy, Ozempic Prices to Keep FallingThe maker of Ozempic and Wegovy obesity drugs said some of the prices could come down, as President Trump called for ...
Novo claims the defendants are steering patients toward compounded semaglutide that has not been approved by regulators; in ...
A daily pill that works like Ozempic can help slimmers lose an average of two stone, trials have found. The study of ...
Some studies have linked the popular weight-loss drugs with a potentially higher risk of eye problems and vision loss. Should ...
Muscle and strength loss in human aging, also known as sarcopenia, can result in trouble with balance and walking, according ...
1d
Investor's Business Daily on MSNNovo Nordisk Slumps As 'Unlawful' Knockoffs Pressure Wegovy, OzempicNovo Nordisk stock slumped Wednesday after saying it expects compounded versions to undercut sales of its obesity drug, ...
Novo Nordisk A/S (NYSE:NVO), the Danish pharmaceutical giant renowned for its weight-loss drug Wegovy and diabetes treatment ...
Some of the most recognizable brand names that could be impacted by new tariffs include Ozempic and Wegovy, two injectable drugs that have grown popular in recent years for their abilities to ...
The Danish firm blamed the move to slash its guidance on intense competition from rivals and copycat drugs in the US.
As of 2024, Brazil's Semaglutide market was estimated at $581 million. The global market size for the GLP-1 (glucagon-like ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results